{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:44:28Z","timestamp":1792748668201,"version":"4.5.0"},"reference-count":88,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277012"],"award-info":[{"award-number":["22277012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20378"],"award-info":[{"award-number":["U22A20378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this work, a series of novel dual inhibitors against both tubulin and histone deacetylase (HDAC) were designed and synthesized by integrating the natural product Millepachine with the key pharmacophore of HDAC inhibitors. Among them, compound 6 exhibited potent antiproliferative activity against 12 cancer cell lines, with IC50 values ranging from 0.020 to 0.244 \u03bcM. Mechanistic investigations revealed that compound 6 inhibited both tubulin polymerization (IC50 2.0 \u03bcM) and HDAC8 (IC50 0.110 \u03bcM), with 54-, 27- and 132-fold selectivity over HDAC1, HDAC4 and HDAC6, respectively. In an ovarian cancer xenograft mouse model, compound 6 exhibited significant inhibitory effect on tumor growth with a favorable safety profile. These findings identify compound 6 as a promising tubulin\/HDAC8 dual inhibitor for further investigation.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01002","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:03:01Z","timestamp":1791788581000},"page":"23622-23650","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of a Novel Dual Inhibitor Targeting Tubulin and Histone Deacetylase 8 for Treatment of the Ovarian Cancer"],"prefix":"10.1021","volume":"69","author":[{"given":"Shaowen","family":"Cai","sequence":"first","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furui","family":"Shi","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Chen","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Shi","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Tang","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-8075","authenticated-orcid":true,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201203"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026102305071961400_cit1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1021\/jm501941q","article-title":"Epigenetics: novel therapeutics targeting epigenetics","volume":"58","author":"Conway","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41392-022-01300-8","article-title":"Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets","volume":"8","author":"Shu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026102305071961400_cit3","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"key":"2026102305071961400_cit4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cmet.2019.03.009","article-title":"Epigenetics in Human Obesity and Type 2 Diabetes","volume":"29","author":"Ling","year":"2019","journal-title":"Cell Metab."},{"key":"2026102305071961400_cit5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/cancers12061664","article-title":"Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy","volume":"12","author":"Verza","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026102305071961400_cit6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026102305071961400_cit7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/med.21437","article-title":"The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat","volume":"37","author":"Zagni","year":"2017","journal-title":"Med. Res. Rev."},{"key":"2026102305071961400_cit8","doi-asserted-by":"publisher","first-page":"116972","DOI":"10.1016\/j.ejmech.2024.116972","article-title":"HDAC8 as a target in drug discovery: Function, structure and design","volume":"280","author":"Zhao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/cad.0000000000000040","article-title":"Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors","volume":"25","author":"Slingerland","year":"2014","journal-title":"Anticancer Drugs"},{"key":"2026102305071961400_cit10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"2026102305071961400_cit11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"2026102305071961400_cit12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1517\/17425255.2013.754011","article-title":"Toxicological and metabolic considerations for histone deacetylase inhibitors","volume":"9","author":"Fraczek","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2026102305071961400_cit13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd2155","article-title":"Why is cancer drug discovery so difficult?","volume":"6","author":"Kamb","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026102305071961400_cit14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2026102305071961400_cit15","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2174\/092986712801215883","article-title":"Designed multiple ligands: basic research vs clinical outcomes","volume":"19","author":"Costantino","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"2026102305071961400_cit16","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug: multitarget drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"2026102305071961400_cit17","first-page":"539","article-title":"Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status","volume":"24","author":"Chobanian","year":"2004","journal-title":"Anticancer Res."},{"key":"2026102305071961400_cit18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13148-015-0157-2","article-title":"Epigenetic treatment of solid tumours: a review of clinical trials","volume":"7","author":"Nervi","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"2026102305071961400_cit19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejmech.2015.03.035","article-title":"Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors","volume":"95","author":"Zhang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit20","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1016\/j.bmc.2013.03.049","article-title":"The discovery of colchicine-SAHA hybrids as a new class of antitumor agents","volume":"21","author":"Zhang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"2026102305071961400_cit21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"2026102305071961400_cit22","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/s1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"2026102305071961400_cit24","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"2026102305071961400_cit25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by Design: A Medicinal Chemist\u2019s Perspective on Multitargeting Compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit26","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med. Res. Rev."},{"key":"2026102305071961400_cit27","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2174\/1871520619666190118120708","article-title":"Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship","volume":"19","author":"Singh","year":"2019","journal-title":"Adv. Anticancer Agents Med. Chem."},{"key":"2026102305071961400_cit28","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology - foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit29","doi-asserted-by":"publisher","first-page":"7245","DOI":"10.1021\/acs.jmedchem.8b00664","article-title":"Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents","volume":"61","author":"He","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit30","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1021\/acs.jmedchem.7b00467","article-title":"Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors","volume":"60","author":"Dong","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit31","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections","volume":"61","author":"Huang","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit32","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1021\/acs.jmedchem.8b01597","article-title":"Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10637-019-00821-4","article-title":"Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug","volume":"38","author":"Chen","year":"2020","journal-title":"Invest. New Drugs"},{"key":"2026102305071961400_cit34","doi-asserted-by":"publisher","first-page":"112831","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit35","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, Synthesis, and 0Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K\/HDAC Inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit36","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit37","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/1078-0432.ccr-14-2820","article-title":"A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma","volume":"21","author":"Galloway","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2026102305071961400_cit38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/bjh.17730","article-title":"Fimepinostat (CUDC-907) in patients with relapsed\/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses","volume":"195","author":"Landsburg","year":"2021","journal-title":"Br. J. Haematol."},{"key":"2026102305071961400_cit39","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s40265-025-02248-z","article-title":"Ifupinostat: First Approval","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"key":"2026102305071961400_cit40","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2174\/1568026617666170104145640","article-title":"Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents","volume":"17","author":"Tangutur","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"2026102305071961400_cit41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tcb.2018.05.001","article-title":"Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton","volume":"28","author":"Steinmetz","year":"2018","journal-title":"Trends Cell Biol."},{"key":"2026102305071961400_cit42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1021\/acs.jnatprod.9b00105","article-title":"Microtubule-Targeting Drugs: More than Antimitotics","volume":"82","author":"Kaul","year":"2019","journal-title":"J. Nat. Prod."},{"key":"2026102305071961400_cit43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2026102305071961400_cit44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/157488406775268200","article-title":"Current state of the art of new tubulin inhibitors in the clinic","volume":"1","author":"Kuppens","year":"2006","journal-title":"Curr. Clin. Pharmacol."},{"key":"2026102305071961400_cit45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026102305071961400_cit46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/34465","article-title":"Structure of the alpha beta tubulin dimer by electron crystallography","volume":"391","author":"Nogales","year":"1998","journal-title":"Nature"},{"key":"2026102305071961400_cit47","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/embor.2008.171","article-title":"Structural insight into the inhibition of tubulin by vinca domain peptide ligands","volume":"9","author":"Cormier","year":"2008","journal-title":"EMBO Rep."},{"key":"2026102305071961400_cit48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature"},{"key":"2026102305071961400_cit49","doi-asserted-by":"publisher","first-page":"13817","DOI":"10.1073\/pnas.1408124111","article-title":"A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs","volume":"111","author":"Prota","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026102305071961400_cit50","doi-asserted-by":"publisher","first-page":"12103","DOI":"10.1038\/ncomms12103","article-title":"Pironetin reacts covalently with cysteine-316 of alpha-tubulin to destabilize microtubule","volume":"7","author":"Yang","year":"2016","journal-title":"Nat. Commun."},{"key":"2026102305071961400_cit51","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/anie.201307749","article-title":"Structural basis of microtubule stabilization by laulimalide and peloruside A","volume":"53","author":"Prota","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"2026102305071961400_cit52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021847118","article-title":"Gatorbulin -1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site","volume":"118","author":"Matthew","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026102305071961400_cit53","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/ijms18081733","article-title":"Taxol((R)): The First Microtubule Stabilizing Agent","volume":"18","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"2026102305071961400_cit54","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2174\/1381612053764706","article-title":"Improving the targeting of tubulin-binding agents: lessons from drug resistance studies","volume":"11","author":"Verrills","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"2026102305071961400_cit55","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"2026102305071961400_cit56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"2026102305071961400_cit57","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","article-title":"An overview of tubulin inhibitors that interact with the colchicine binding site","volume":"29","author":"Lu","year":"2012","journal-title":"Pharm. Res."},{"key":"2026102305071961400_cit58","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1007\/s11095-012-0726-4","article-title":"Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis","volume":"29","author":"Wang","year":"2012","journal-title":"Pharm. Res."},{"key":"2026102305071961400_cit59","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","article-title":"Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents","volume":"102","author":"Stengel","year":"2010","journal-title":"Br. J. Cancer"},{"key":"2026102305071961400_cit60","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1021\/acs.jmedchem.6b00463","article-title":"Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth","volume":"59","author":"Perez-Perez","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit61","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.fitote.2012.08.001","article-title":"Cytotoxic and apoptotic effects of constituents from Millettia pachycarpa Benth","volume":"83","author":"Ye","year":"2012","journal-title":"Fitoterapia"},{"key":"2026102305071961400_cit62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejmech.2013.01.007","article-title":"Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents","volume":"62","author":"Cao","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit63","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1021\/jm500849z","article-title":"Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors","volume":"57","author":"Yang","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit64","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1016\/j.bmc.2013.02.002","article-title":"Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors","volume":"21","author":"Wang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"2026102305071961400_cit65","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.bmc.2014.02.028","article-title":"Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents","volume":"22","author":"Wang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"2026102305071961400_cit66","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ejmech.2012.06.034","article-title":"Design, synthesis, and structure-activity relationship studies of novel millepachine derivatives as potent antiproliferative agents","volume":"54","author":"Wang","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit67","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1074\/jbc.ra117.001658","article-title":"The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in beta-tubulin","volume":"293","author":"Yang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"2026102305071961400_cit68","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","article-title":"The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo","volume":"8","author":"Chao","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"2026102305071961400_cit69","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12935-014-0112-x","article-title":"Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms","volume":"14","author":"Liu","year":"2014","journal-title":"Cancer Cell Int."},{"key":"2026102305071961400_cit70","doi-asserted-by":"publisher","first-page":"100765","DOI":"10.1039\/c6ra19917h","article-title":"Effects of paclitaxel (PTX) prodrug-based self-assembly peptide hydrogels combined with suberoylanilide hydroxamic acid (SAHA) for PTX-resistant cancer and synergistic antitumor therapy","volume":"6","author":"Shu","year":"2016","journal-title":"RSC Adv."},{"key":"2026102305071961400_cit71","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ejmech.2016.11.033","article-title":"3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity","volume":"125","author":"Lee","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit72","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1021\/acs.jmedchem.8b00050","article-title":"Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4","volume":"61","author":"Lamaa","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit73","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.bmcl.2019.07.045","article-title":"Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors","volume":"29","author":"Wang","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026102305071961400_cit74","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ejmech.2018.10.066","article-title":"1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase","volume":"162","author":"Lai","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit75","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1021\/acs.jmedchem.1c00413","article-title":"Efficient Synthesis and Bioevaluation of Novel Dual Tubulin\/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents","volume":"64","author":"Peng","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit76","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1021\/acs.jmedchem.2c00681","article-title":"Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit77","doi-asserted-by":"publisher","first-page":"106112","DOI":"10.1016\/j.bioorg.2022.106112","article-title":"Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma","volume":"128","author":"Tang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"2026102305071961400_cit78","doi-asserted-by":"publisher","first-page":"115529","DOI":"10.1016\/j.ejmech.2023.115529","article-title":"Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin\/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo","volume":"257","author":"Zhu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit79","doi-asserted-by":"publisher","first-page":"116301","DOI":"10.1016\/j.ejmech.2024.116301","article-title":"Design and biological evaluation of dual tubulin\/HDAC inhibitors based on millepachine for treatment of prostate cancer","volume":"268","author":"Xie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit80","doi-asserted-by":"publisher","first-page":"114573","DOI":"10.1016\/j.ejmech.2022.114573","article-title":"Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors","volume":"240","author":"Hauguel","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305071961400_cit81","doi-asserted-by":"publisher","first-page":"12140","DOI":"10.1021\/acs.jmedchem.2c00853","article-title":"First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation","volume":"65","author":"Yue","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit82","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/carcin\/bgt087","article-title":"Millepachine, a novel chalcone, induces G2\/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo","volume":"34","author":"Wu","year":"2013","journal-title":"Carcinogenesis"},{"key":"2026102305071961400_cit83","doi-asserted-by":"publisher","first-page":"103522","DOI":"10.1016\/j.bioorg.2019.103522","article-title":"Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines","volume":"95","author":"Tilekar","year":"2020","journal-title":"Bioorg. Chem."},{"key":"2026102305071961400_cit84","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.2174\/0929867322666150114163732","article-title":"Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments","volume":"22","author":"Ji","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"2026102305071961400_cit85","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/dna.2019.4877","article-title":"The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair","volume":"39","author":"Deng","year":"2020","journal-title":"DNA Cell Biol."},{"key":"2026102305071961400_cit86","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"2026102305071961400_cit87","doi-asserted-by":"publisher","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026102305071961400_cit88","doi-asserted-by":"publisher","first-page":"173975","DOI":"10.1016\/j.ejphar.2021.173975","article-title":"MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma","volume":"898","author":"Yan","year":"2021","journal-title":"Eur. J. Pharmacol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01002","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23622\/68814860\/jm6c01002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23622\/68814860\/jm6c01002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:29:54Z","timestamp":1792747794000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/23622\/5448709\/Discovery-of-a-Novel-Dual-Inhibitor-Targeting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":88,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01002","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}